Man Group
RARE icon

Man Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Man Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.47M Buy
213,352
+134,981
+172% +$3.04M 0.01% 1213
2025
Q4 		$1.8M Buy
78,371
+71,219
+996% +$2.34M ﹤0.01% 1485
2025
Q3 		$215K Sell
7,152
-177,025
-96% -$5.31M ﹤0.01% 2090
2025
Q2 		$6.7M Sell
184,177
-270,971
-60% -$9.77M 0.01% 932
2025
Q1 		$16.5M Buy
455,148
+157,754
+53% +$6.56M 0.04% 524
2024
Q4 		$12.5M Sell
297,394
-29,809
-9% -$1.48M 0.03% 640
2024
Q3 		$18.2M Sell
327,203
-301,523
-48% -$15.4M 0.05% 482
2024
Q2 		$25.8M Buy
628,726
+475,085
+309% +$20.3M 0.07% 358
2024
Q1 		$7.17M Buy
153,641
+65,830
+75% +$3.11M 0.02% 839
2023
Q4 		$4.2M Buy
+87,811
New +$3.4M 0.01% 1022
2023
Q3 		– Sell
-42,277
Closed -$1.68M – 1381
2023
Q2 		$1.95M Buy
+42,277
New +$1.96M 0.01% 1209
2023
Q1 		– Sell
-38,211
Closed -$1.64M – 1402
2022
Q4 		$1.77M Buy
38,211
+3,773
+11% +$148K 0.01% 1151
2022
Q3 		$1.43M Buy
+34,438
New +$1.77M 0.01% 1176
2022
Q2 		– Sell
-6,724
Closed -$414K – 1224
2022
Q1 		$488K Buy
+6,724
New +$468K ﹤0.01% 1592
2021
Q2 		– Sell
-16,645
Closed -$1.9M – 2069
2021
Q1 		$1.9M Sell
16,645
-28,503
-63% -$3.88M 0.01% 1126
2020
Q4 		$6.25M Buy
45,148
+12,555
+39% +$1.49M 0.03% 675
2020
Q3 		$2.68M Buy
32,593
+4,016
+14% +$333K 0.01% 1090
2020
Q2 		$2.23M Sell
28,577
-8,771
-23% -$581K 0.01% 1024
2020
Q1 		$1.66M Sell
37,348
-58,795
-61% -$3.05M 0.01% 961
2019
Q4 		$4.11M Buy
96,143
+44,797
+87% +$1.85M 0.01% 1065
2019
Q3 		$2.2M Sell
51,346
-16,217
-24% -$881K 0.01% 1212
2019
Q2 		$4.29M Sell
67,563
-10,142
-13% -$646K 0.02% 1015
2019
Q1 		$5.39M Buy
77,705
+34,662
+81% +$1.98M 0.02% 879
2018
Q4 		$1.87M Sell
43,043
-6,341
-13% -$347K 0.01% 1246
2018
Q3 		$3.77M Buy
+49,384
New +$4.02M 0.01% 1147

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Man Group's RARE Position: Q1 2026 in Review

Man Group increased its Ultragenyx Pharmaceutical (RARE) stake by 172% in Q1 2026, buying an estimated $3.04M and bringing the position to 213,352 shares worth $4.47M. The position accounts for 0.01% of the portfolio, ranked #1213.

Man Group first reported a position in RARE in Q3 2018 and has held it in 25 quarters since. The position peaked at $25.8M in Q2 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Man Group held 213,352 shares of Ultragenyx Pharmaceutical worth $4.47M as of Q1 2026.
  • Man Group bought 134,981 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $3.04M.
  • Ultragenyx Pharmaceutical made up 0.01% of Man Group's portfolio in Q1 2026, its #1213 holding.
  • Man Group first reported a position in Ultragenyx Pharmaceutical in Q3 2018 and has held it in 25 quarters since.
  • Man Group's Ultragenyx Pharmaceutical position peaked at $25.8M in Q2 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.